S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Servier
Servier
AstraZeneca
Amgen
DualityBio Inc.
Tanabe Pharma America, Inc.
Eli Lilly and Company
Bolt Biotherapeutics, Inc.
Yuhan Corporation
Bristol-Myers Squibb
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Evopoint Biosciences Inc.
Cantargia AB
Institut Bergonié